Related Experiment Video

Updated: Jun 28, 2026

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis
09:33

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis

Published on: March 20, 2026

Antiangiogenic therapy in brain tumors

Sajani S Lakka1, Jasti S Rao

  • 1Department of Cancer Biology and Pharmacology, University of Illinois College of Medicine at Peoria, 1 Illini Drive, Peoria, IL 61605, USA.

Expert Review of Neurotherapeutics
|October 22, 2008
PubMed

Insights

Targeting angiogenesis, the formation of new blood vessels, is a key strategy against malignant brain tumors. Research is advancing novel antiangiogenic agents and treatment regimens for glioblastoma, showing promising therapeutic potential.

Area of Science:

  • Oncology
  • Vascular Biology
  • Neuro-oncology

Background:

  • Malignant brain tumors, such as glioblastoma, are highly vascular and depend on angiogenesis for growth.
  • Inhibiting angiogenesis, the process of new blood vessel formation, is a promising therapeutic strategy for brain tumors.

Purpose of the Study:

  • To review current antiangiogenic targets for brain tumor treatment.
  • To discuss the challenges and future directions in antiangiogenic therapy for brain tumors.

Main Methods:

  • Literature review of antiangiogenic targets and therapeutic approaches for brain tumors.
  • Analysis of ongoing clinical trials investigating angiogenesis inhibitors in glioblastoma.

Main Results:

  • Angiogenesis is crucial for malignant brain tumor progression.
  • Several classes of molecules regulate angiogenesis, and novel inhibitors are under development.
  • Preliminary studies of antiangiogenic blockade in glioblastoma are promising, with several clinical trials underway.

Conclusions:

  • Understanding the angiogenic process, its mediators, and optimizing drug schedules are critical for effective antiangiogenic therapy.
  • Combining antiangiogenic agents with other treatment modalities may lead to improved efficacy for brain tumors.

More Related Videos

A Novel High-resolution In vivo Imaging Technique to Study the Dynamic Response of Intracranial Structures to Tumor Growth and Therapeutics12:09

A Novel High-resolution In vivo Imaging Technique to Study the Dynamic Response of Intracranial Structures to Tumor Growth and Therapeutics

Published on: June 16, 2013

Modeling Brain Metastasis Via Tail-Vein Injection of Inflammatory Breast Cancer Cells05:02

Modeling Brain Metastasis Via Tail-Vein Injection of Inflammatory Breast Cancer Cells

Published on: February 4, 2021

Related Concept Videos

Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...